Board Members: Michael Friedman

Michael A. Friedman, M.D.

An executive officer from a California Research Institute
Appointed by the Treasurer

Dr. Michael Friedman is Chief Executive Officer of City of Hope, a cancer research and treatment institution dedicated to innovation in basic and clinical biomedical research and delivery of compassionate, world-class patient care. Dr. Friedman was formerly senior vice president of research and development, medical and public policy, for Pharmacia Corporation. In addition, he served as chief medical officer for biomedical preparedness at the Pharmaceutical Research and Manufacturers of America following the events of September 11, 2001. Dr. Friedman had previously served as FDA Deputy Commissioner and was later tapped by the Clinton administration to serve as acting commissioner of the agency. He helped to streamline the FDA’s review and approval process and provided oversight of evaluations for drugs, biologics, medical devices and food ingredients.

In 1983, Dr. Friedman was chief of the Clinical Investigations Branch of the Division of Cancer Treatment at the National Cancer Institute, and went on to become associate director of the Division’s Cancer Therapy Evaluation Program. Before joining the NCI, Dr. Friedman spent nearly a decade at the University of California at San Francisco, serving as associate professor of medicine, eventually becoming interim director of the Cancer Research Institute.

Dr. Friedman has received numerous commendations, including the Surgeon General’s Medallion in 1999. He received his Bachelor of Arts degree, magna cum laude, from Tulane University and a Doctorate in Medicine from the University of Texas. He completed postdoctoral training at Stanford University and the National Cancer Institute, and is board certified in Internal Medicine and Medical Oncology.

Alternate Member

Theodore G. Krontiris, MD, PhD
Director Emeritus, Comprehensive Cancer Center
Distinguished Professor, Molecular Medicine

Theodore Krontiris, MD, PhD, joined City of Hope (COH) in 1996 as chair of a newly established Department of Molecular Medicine; he was Executive Vice President, Medical and Scientific Affairs, and Director of COH’s NCI-designated Comprehensive Cancer Center from 2001 to 2007.  Prior to coming to COH, Dr. Krontiris held several medical and teaching positions at Tufts University School of Medicine and Tufts New England Medical Center Hospitals, where he was founding director of the Graduate Program in Genetics at the Sackler Graduate School.  He received his medical degree and PhD from the Albert Einstein College of Medicine in New York, as well as residency and fellowship training at Brigham and Women’s Hospital and the Dana-Farber Cancer Institute in Boston.
 

© 2013 California Institute for Regenerative Medicine